Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

EMBRACE1: Prostate Biorepository

This study has been completed.
Information provided by (Responsible Party):
Caris Science, Inc. Identifier:
First received: December 16, 2011
Last updated: June 7, 2016
Last verified: June 2016
The objective of this multi-center prospective observational clinical study is to evaluate the clinical performance of the Carisome Prostate assay as an aid in the diagnosis of prostate cancer in men that have been scheduled for a prostate biopsy. Primarily, results of the Carisome Prostate assay will be compared with pathology results of prostate biopsy procedures. Secondarily, the performance of the Carisome Prostate test will be compared to the current standard of care for the detection of prostate cancer.

Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of a Novel Circulating Microvesicle-Based Multi-analyte Assay for the Detection of Prostate Cancer in Men With Elevated Risk for Prostate Cancer; the EMBRACE1 Study

Resource links provided by NLM:

Further study details as provided by Caris Science, Inc.:

Primary Outcome Measures:
  • Carisome Prostate Assay with prostate biopsy outcome [ Time Frame: up to 6 months ] [ Designated as safety issue: No ]
    Association of Carisome Prostate Assay result with prostate biopsy outcome

Biospecimen Retention:   Samples With DNA

Enrollment: 1290
Study Start Date: December 2011
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Routine prostate biopsy patients


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Men scheduled for routine prostate biopsy

Inclusion Criteria:

  • Men scheduled for a routine prostate biopsy expected to produce a pathology evaluation and report
  • Blood draw within 7 days prior to scheduled prostate biopsy procedure
  • Blood draw on the day of but prior to biopsy

Exclusion Criteria:

  • Any previous diagnosis of cancer with the exception of non-melanoma skin cancer
  • Any prior or ongoing treatment for prostate cancer including prostatectomy or hormone therapy
  • Prostate biopsy within one month of blood draw
  • Previous enrollment in the Caris Life Sciences Biorepository
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01499381

United States, Arizona
Caris Science, Inc.
Phoenix, Arizona, United States
Sponsors and Collaborators
Caris Science, Inc.
  More Information

Responsible Party: Caris Science, Inc. Identifier: NCT01499381     History of Changes
Other Study ID Numbers: CRMDA-0001-1011 
Study First Received: December 16, 2011
Last Updated: June 7, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on October 26, 2016